FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164483595> ?p ?o ?g. }

• W3164483595 endingPage "1167" @default.
• W3164483595 startingPage "1167.1" @default.
• W3164483595 abstract "Background: Activation and expansion of regulatory T cells (Tregs) has been proposed as a strategy to treat autoimmunity. When administered in low doses, IL-2 expands and activates Tregs leading to clinical response in several autoimmune diseases. However, the narrow therapeutic window of IL-2 results in loss of selectivity for Tregs and concurrent activation of conventional T cells (Tconv) and NK cells, limiting its clinical utility. This loss of selectivity may negate the clinical benefit of Treg activation and lead to dose-limiting side effects. PT101 is a novel engineered variant of IL-2 fused to an Fc protein backbone which in preclinical studies selectively activates Tregs without expanding Tconv or NK cells. PT101 is in clinical development for the treatment of patients with autoimmune diseases. Objectives: To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PT101 after a single dose in healthy human volunteers. Methods: We conducted a randomized, double-blind, single-ascending dose trial of PT101 or placebo (3:1 allocation). Five dose levels from 1 mg to 10 mg were administered by subcutaneous injection. Adverse events, physical examination findings, and clinical laboratory results were assessed for 29 days. Serum PT101 levels and antidrug antibody were assessed. Changes in mononuclear cell populations were measured in peripheral blood by flow cytometry. Results: 56 subjects were administered PT101 or placebo. All subjects completed the study. There were no deaths, serious adverse events, dose limiting toxicities, or clinically significant changes in vital sign, ECG, or laboratory results. All adverse events were Grade 1 or 2 and self-limited. Injection site reactions were the most common adverse event. Transient increases in eosinophil counts were observed in some subjects, consistent with the known class effect of IL-2. Peak levels of PT101 occurred 11.0 to 14.6 hours after administration, and declined with a mean half-life of 20.4 to 28.3 hours, demonstrating linear exposure through the dose range. No anti-drug antibodies were induced. PT101 caused dose-related expansion of Tregs that plateaued at doses between 3.5 and 10 mg. Mean maximum expansion above baseline was 3.6-fold for total Tregs and 72.5-fold for the CD25bright subset of Tregs. Maximal expansion was observed by Day 8-10 with a return toward baseline by Day 29. Over 80% of subjects achieved a 2-fold or greater expansion of total Tregs (Table 1). No significant expansion of Tconv or NK cells was observed at any dose level. Table 1. Percent Total Treg Responders Fold Change Total Tregs Placebo (n=14) 1 mg (n=6) 3.5 mg (n=12) 5 mg (n=12) 7.5 mg (n=6) 10 mg (n=6) ≥ 2X 7% 33% 83% 83% 100% 100% ≥ 3X 0% 0% 58% 75% 33% 50% ≥ 4X 0% 0% 24% 42% 33% 17% Conclusion: PT101 was safe and well tolerated after a single dose in healthy volunteers. Marked expansion of both total Treg and CD25bright Treg cells was observed. High selectivity for Tregs was observed with no significant expansion of pro-inflammatory Tconv and NK cells even at the highest dose studied. These results support the therapeutic potential of PT101 in planned multiple dose studies in systemic lupus erythematosus, ulcerative colitis, and other autoimmune diseases. References: [1]Klatzmann, D., Abbas, A. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 15, 283–294 (2015) Acknowledgements: Pandion Therapeutics acknowledges the participants and research staff who contributed to this clinical trial Disclosure of Interests: John S Sundy Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Kevin L. Otipoby Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Nathan Higginson-Scott Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Jyothsna Visweswaraiah Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Erik Sampson Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Katalin Kis-Toth Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Adrianne Monsef Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Parika Petaipimol Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, David Essayan Consultant of: Pandion Therapeutics, Mary Ellen Cosenza Consultant of: Pandion Therapeutics, Rahul Kakkar Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics, Jo Viney Shareholder of: Pandion Therapeutics, Employee of: Pandion Therapeutics" @default.
• W3164483595 created "2021-06-07" @default.
• W3164483595 creator A5000905084 @default.
• W3164483595 creator A5010781580 @default.
• W3164483595 creator A5024553881 @default.
• W3164483595 creator A5034878963 @default.
• W3164483595 creator A5047534039 @default.
• W3164483595 creator A5048802900 @default.
• W3164483595 creator A5052497081 @default.
• W3164483595 creator A5056521508 @default.
• W3164483595 creator A5059494650 @default.
• W3164483595 creator A5068996751 @default.
• W3164483595 creator A5082303962 @default.
• W3164483595 creator A5088219614 @default.
• W3164483595 date "2021-05-19" @default.
• W3164483595 modified "2023-10-17" @default.
• W3164483595 title "AB0282 SAFETY, TOLERABILITY AND SELECTIVE EXPANSION OF REGULATORY T CELLS BY A SINGLE DOSE OF THE NOVEL IL-2 MUTEIN PT101 IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS" @default.
• W3164483595 doi "https://doi.org/10.1136/annrheumdis-2021-eular.1200" @default.
• W3164483595 hasPublicationYear "2021" @default.
• W3164483595 type Work @default.
• W3164483595 sameAs 3164483595 @default.
• W3164483595 citedByCount "2" @default.
• W3164483595 countsByYear W31644835952022 @default.
• W3164483595 countsByYear W31644835952023 @default.
• W3164483595 crossrefType "journal-article" @default.
• W3164483595 hasAuthorship W3164483595A5000905084 @default.
• W3164483595 hasAuthorship W3164483595A5010781580 @default.
• W3164483595 hasAuthorship W3164483595A5024553881 @default.
• W3164483595 hasAuthorship W3164483595A5034878963 @default.
• W3164483595 hasAuthorship W3164483595A5047534039 @default.
• W3164483595 hasAuthorship W3164483595A5048802900 @default.
• W3164483595 hasAuthorship W3164483595A5052497081 @default.
• W3164483595 hasAuthorship W3164483595A5056521508 @default.
• W3164483595 hasAuthorship W3164483595A5059494650 @default.
• W3164483595 hasAuthorship W3164483595A5068996751 @default.
• W3164483595 hasAuthorship W3164483595A5082303962 @default.
• W3164483595 hasAuthorship W3164483595A5088219614 @default.
• W3164483595 hasBestOaLocation W31644835951 @default.
• W3164483595 hasConcept C111113717 @default.
• W3164483595 hasConcept C112705442 @default.
• W3164483595 hasConcept C126322002 @default.
• W3164483595 hasConcept C137061746 @default.
• W3164483595 hasConcept C142724271 @default.
• W3164483595 hasConcept C185592680 @default.
• W3164483595 hasConcept C197934379 @default.
• W3164483595 hasConcept C202751555 @default.
• W3164483595 hasConcept C203014093 @default.
• W3164483595 hasConcept C204787440 @default.
• W3164483595 hasConcept C27081682 @default.
• W3164483595 hasConcept C2776090121 @default.
• W3164483595 hasConcept C2778375690 @default.
• W3164483595 hasConcept C2780850621 @default.
• W3164483595 hasConcept C3875195 @default.
• W3164483595 hasConcept C535046627 @default.
• W3164483595 hasConcept C55493867 @default.
• W3164483595 hasConcept C71924100 @default.
• W3164483595 hasConcept C8891405 @default.
• W3164483595 hasConcept C98274493 @default.
• W3164483595 hasConceptScore W3164483595C111113717 @default.
• W3164483595 hasConceptScore W3164483595C112705442 @default.
• W3164483595 hasConceptScore W3164483595C126322002 @default.
• W3164483595 hasConceptScore W3164483595C137061746 @default.
• W3164483595 hasConceptScore W3164483595C142724271 @default.
• W3164483595 hasConceptScore W3164483595C185592680 @default.
• W3164483595 hasConceptScore W3164483595C197934379 @default.
• W3164483595 hasConceptScore W3164483595C202751555 @default.
• W3164483595 hasConceptScore W3164483595C203014093 @default.
• W3164483595 hasConceptScore W3164483595C204787440 @default.
• W3164483595 hasConceptScore W3164483595C27081682 @default.
• W3164483595 hasConceptScore W3164483595C2776090121 @default.
• W3164483595 hasConceptScore W3164483595C2778375690 @default.
• W3164483595 hasConceptScore W3164483595C2780850621 @default.
• W3164483595 hasConceptScore W3164483595C3875195 @default.
• W3164483595 hasConceptScore W3164483595C535046627 @default.
• W3164483595 hasConceptScore W3164483595C55493867 @default.
• W3164483595 hasConceptScore W3164483595C71924100 @default.
• W3164483595 hasConceptScore W3164483595C8891405 @default.
• W3164483595 hasConceptScore W3164483595C98274493 @default.
• W3164483595 hasIssue "Suppl 1" @default.
• W3164483595 hasLocation W31644835951 @default.
• W3164483595 hasOpenAccess W3164483595 @default.
• W3164483595 hasPrimaryLocation W31644835951 @default.
• W3164483595 hasRelatedWork W2028648326 @default.
• W3164483595 hasRelatedWork W2112620969 @default.
• W3164483595 hasRelatedWork W2122556001 @default.
• W3164483595 hasRelatedWork W2194222775 @default.
• W3164483595 hasRelatedWork W2626992247 @default.
• W3164483595 hasRelatedWork W2922882148 @default.
• W3164483595 hasRelatedWork W3120853613 @default.
• W3164483595 hasRelatedWork W3159937175 @default.
• W3164483595 hasRelatedWork W3207313530 @default.
• W3164483595 hasRelatedWork W4319063555 @default.
• W3164483595 hasVolume "80" @default.
• W3164483595 isParatext "false" @default.
• W3164483595 isRetracted "false" @default.
• W3164483595 magId "3164483595" @default.
• W3164483595 workType "article" @default.